RESUMO
Objective@#To investigate the prevalence and influencing factors of falls among elderly patients with comorbidity of chronic diseases in Chongqing Municipality, so as to provide insights into preventing measures of falls.@*Methods@#Elderly patients with comorbidity of chronic diseases admitted to a level A tertiary hospital of Chongqing Municipality from July 2022 to December 2022 were recruited. Participants' demographics, physical component and fall condition were collected using a questionnaire survey. Incidence of falls was descriptively analyzed, and factors affecting falls among elderly patients with comorbidity of chronic diseases were identified using a multivariable logistic regression model.@*Results@#A total of 344 questionnaires were allocated, and 338 valid questionnaires were recovered, with an effective rate of 98.26%. There were 195 men (57.69%) and 143 women (42.31%), with a mean age of (77.10±7.29) years. There were 171 (50.59%), 115 (34.02%), 38 (11.24%) and 14 (4.14%) patients suffering from 2, 3, 4 and 5 chronic diseases, respectively. The incidence of falls during recent six months was 22.49%. Multivariable logistic regression analysis identified history of vertigo in last 6 months (OR=2.720, 95%CI: 1.409-5.249), fear of falling (OR=8.725, 95%CI: 4.572-16.653) and adaptation of living environments to ageing (OR=0.257, 95%CI: 0.130-0.509) as factors affecting elderly patients with comorbidity of chronic diseases.@*Conclusion@#The Elderly patients with comorbidity of chronic diseases who have a history of vertigo, fear of falling, and living environments that are not age-adapted are at higher risks of falls.
RESUMO
Objective: The objective of this study was to investigate the molecular mechanisms involved in rapamycin-induced inhibition of tumor growth. Materials and Methods: Murine S180 sarcoma cells were subcutaneously injected into mice, and the tumor-bearing mice were randomly divided into three groups (vehicle control, 2 mg/kg rapamycin, and 4 mg/kg rapamycin). The effect of rapamycin on tumor growth was determined by measuring tumor volume. Mammalian target of rapamycin (mTOR), Beclin1, ULK1, LC3, Notch1, CD133, and CD90 expressions was confirmed using confocal microscopy and Western blotting. Results: The tumor growth inhibition rates induced by high-dose and low-dose rapamycin were 48.8% and 30.1%, respectively. Beclin1 and ULK1 expressions and the LC3-II/LC3-I ratio in tumor tissues were altered by rapamycin, whereas mTOR, Notch1, CD133, and CD90 expressions were significantly inhibited by rapamycin in immunofluorescence assays. Western blotting also showed similar results. Conclusion: Tumor growth delay induced by rapamycin may be associated with the suppression of the cancer stem cell phenotype (Notch1, CD133, and CD90) and promotion of autophagy (mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio) in the murine S180 sarcoma model